March 28, 2023 by Jason Wertheimer Sonoma Biotherapeutics and Regeneron Announce Collaboration to Discover, Develop and Commercialize Treg Cell Therapies for Autoimmune Diseases Read More
November 10, 2022 by Jason Wertheimer Sonoma Biotherapeutics to Present Preclinical Data from Novel Treg Cell Therapy for Rheumatoid Arthritis at American College of Rheumatology Convergence 2022 Read More
September 7, 2022 by Jason Wertheimer Sonoma Biotherapeutics Appoints Jessica Stitt as Chief Financial Officer Read More
August 24, 2022 by Jason Wertheimer Sonoma Biotherapeutics Enters Long-Term Lease Agreement to Establish a Treg Cell Therapy R&D and Manufacturing Center Read More
August 17, 2022 by Jason Wertheimer Sonoma Biotherapeutics Expands Board of Directors with Appointments of Katina Dorton, J.D., MBA, and John Davis, M.D., MPH Read More
June 8, 2022 by Jason Wertheimer Sonoma Biotherapeutics Announces FDA Clearance of Investigational New Drug Application for SBT115301, an Effector T Cell-Modulating Biologic for Autoimmune Diseases Read More
November 16, 2021 by Jason Wertheimer Sonoma Biotherapeutics Appoints Heidi Hagen, MBA as Chief Technical Officer Read More
September 16, 2021 by Jason Wertheimer Sonoma Biotherapeutics Expands Leadership Team with the Appointment of Doug Sheehy, J.D., as Chief Legal Officer and Secretary Read More
August 4, 2021 by Jason Wertheimer Sonoma Biotherapeutics Raises $265 Million in an Oversubscribed Series B Financing to Translate the Promise of Cell Therapy into Curative Medicines for Autoimmune and Other Inflammatory Diseases Read More
September 30, 2020 by Jason Wertheimer Sonoma Biotherapeutics Expands Series A Financing to $70 Million and Appoints Key Executives to Advance Regulatory T-cell Therapies in Autoimmune and Degenerative Diseases Read More